The mixed blessing of AMPK signaling in Cancer treatments

Mehrshad Sadria1, Deokhwa Seo2, Anita T Layton3,4

  • 1Department of Applied Mathematics, University of Waterloo, Waterloo, Ontario, Canada. msadria@uwaterloo.ca.

BMC Cancer
|January 26, 2022
PubMed
Abstract

Insights

AMP-activated protein kinase (AMPK) has dual roles in cancer, acting as a tumor suppressor early on but potentially promoting it later. Computational models reveal strategies to target AMPK and mTORC pathways for cancer therapy.

Area of Science:

  • Cancer Biology
  • Metabolic Signaling
  • Computational Modeling

Background:

  • Cancer cells alter nutrient metabolism for growth.
  • AMP-activated protein kinase (AMPK) regulates cellular energy and metabolism.
  • AMPK's role in cancer is complex, acting as a tumor suppressor pre-cancer but having dual roles post-cancer onset.

Purpose of the Study:

  • To investigate the paradoxical roles of AMPK in cancer.
  • To simulate the effects of targeting key metabolic signaling nodes, including AMPK and mTORC.
  • To explore potential therapeutic strategies based on computational modeling.

Main Methods:

  • Developed an ordinary differential equation-based mechanistic model of AMPK-mTORC signaling.
  • Parametrized the model using existing experimental data.
  • Simulated pharmacological interventions targeting AMPK, mTORC, and their modulators.

Main Results:

  • AMPK activation affects mTORC differently based on nutrient availability.
  • SIRT1 inhibition impacts mTORC only in low-nutrient conditions.
  • DEPTOR abundance and AMPK activity intricately influence cell proliferation and survival.
  • Simultaneous mTORC2 inhibition and AMPK activation may suppress both proliferation and survival.

Conclusions:

  • Model simulations elucidate the complex interplay of metabolic pathways in tumorigenesis.
  • Findings offer insights into novel therapeutic strategies targeting cancer metabolism.
  • Clarified the dual role of AMPK in cancer progression and survival.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.1K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.0K